Trevena Inc (TRVN)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Trevena Inc chart...

About the Company

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders.

Employees

25

CEO

Carrie Bourdow

Exchange

NASDAQ

Website

www.trevena.com

$0M

Total Revenue

25

Employees

$76M

Market Capitalization

-1.28

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TRVN News

Trevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in China

10mon ago, source: Hosted on MSN

Shares of Trevena Inc. exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner ...

Trevena Inc TRVN

10d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Trevena faces Nasdaq delisting over share price

12d ago, source: Investing

Trevena Inc . (NASDAQ: NASDAQ:TRVN), a biopharmaceutical company, is confronting the risk of being delisted from the Nasdaq Capital Market after failing to meet the minimum bid price and ...

Trevena, Inc. (TRVN) Stock Historical Prices & Data - Yahoo Finance

2y ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Trevena, Inc. Common Stock (TRVN)

3y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17%

10mon ago, source: Hosted on MSN

The top performers on the NASDAQ Composite were Trevena Inc (NASDAQ:TRVN) which rose 382.25% to 3.11, Ohmyhome Ltd (NASDAQ:OMH) which was up 328.71% to settle at 25.98 and Bellicum Pharmaceuticals ...

Trevena Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Trevena, Inc. Common Stock (TRVN)

6y ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Trevena faces Nasdaq delisting over share price

12d ago, source: Investing

Trevena Inc . (NASDAQ: NASDAQ:TRVN), a biopharmaceutical company, is confronting the risk of being delisted from the Nasdaq Capital Market after failing to meet the minimum bid price and stockholders' ...

Trevena, Inc. (TRVN)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...